🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hamburg
Clinical trial register · Germany

Clinical Trials in Hamburg, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf74 AstraZeneca56 Janssen Research & Development, LLC33 Eli Lilly and Company30 Novartis Pharmaceuticals26
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Hamburg

889 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)
NCT07001280Hereditary Angioedemas
CSL Behring
Observational
200
Ulm, Frankfurt am Main, Hanover, Leipzig, Hamburg, Berlin
2025-07-21
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
NCT07079631Metastatic Colorectal Cancer
DrugsBNT314·Pumitamig·Bevacizumab
BioNTech SE
Phase 1/2
482
Hamburg
2025-07-18
Recruiting
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma
DrugsBevacizumab biosimilar·Calderasib·Cetuximab·Adrucil
Merck Sharp & Dohme LLC
Phase 3
477
Essen, Berlin, Hamburg
2025-07-16
Recruiting
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
NCT07013474COVID-19 Infection
DrugsIbuzatrelvir·Remdesivir
Pfizer
Phase 3
300
München, Cologne, Hamburg, Rostock, Trier, Villingen-Schwenningen, Wuppertal
2025-07-14
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216Alzheimer's Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
586
Mannheim, Münster, Mainz, Berlin, Aachen, Bremen, Hamburg, Munich
2025-07-14
Recruiting
A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care.
NCT06832722Shock, Cardiogenic
4TEEN4 Pharmaceuticals GmbH
Phase 1/2
90
Berlin, Freiburg im Breisgau, Hamburg, Leipzig, Mannheim
2025-07-13
Recruiting
EEG Measurements to Capture DBS-induced Electric Potentials
NCT07115394Deep Brain Stimulation, Parkinson's Disease
Universitätsklinikum Hamburg-Eppendorf
Observational
20
Hamburg
2025-07-11
Active, closed
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT06991556Metastatic Hormone-sensitive Prostate Cancer
DrugsLuxdegalutamide·Abiraterone·Enzalutamide
Novartis Pharmaceuticals
Phase 2
168
Düsseldorf, Hamburg, Lübeck, Nürtingen
2025-07-07
Recruiting
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
NCT06863272Castration-Resistant Prostatic Cancer, Metastasis
DrugsOpevesostat·Ifinatamab Deruxtecan·Abiraterone·Enzalutamide
Merck Sharp & Dohme LLC
Phase 1/2
360
Heidelberg, Ulm, Jena, Hamburg
2025-07-03
Active, closed
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
NCT06981078Chronic Obstructive Pulmonary Disease
DrugVerekitug
Upstream Bio Inc.
Phase 2
666
Aschaffenburg, Augsburg, Bamberg, München, Cottbus, Hamburg, Darmstadt, Frankfurt am Main
2025-07-02
Recruiting
A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults
NCT06937931Cervical Dystonia
DrugCorabotase
Ipsen
Phase 2
132
Haag in Oberbayern, Hamburg, Troisdorf, Tübingen
2025-06-30
Recruiting
Patient Experience of Transoral Versus Transnasal Awake Tracheal Intubation
NCT06955884Airway Management, Fiberoptic Guided Intubation, Patient Experience
Universitätsklinikum Hamburg-Eppendorf
Observational
198
Hamburg
2025-06-30
Active, closed
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
NCT06979531Primary Sjögren's Syndrome
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
180
Bad Doberan, Hamburg, Hanover, Heidelberg, Munich
2025-06-30
Recruiting
Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
NCT05903833Recurrent Vulvar Cancer, Persistent Vulvar Cancer, Metastatic Vulva Cancer, Locally Advanced Vulvar Cancer
DrugsLenvatinib·Pembrolizumab
AGO Research GmbH
Phase 2
42
Augsburg, Bad Homburg, Dresden, Düsseldorf, Essen, Göttingen, Hamburg, Hanau
2025-06-24
Active, closed
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
NCT06959225Hidradenitis Suppurativa
DrugRuxolitinib
Incyte Corporation
Phase 3
580
Berlin, Bochum, Darmstadt, Dresden, Erlangen, Hamburg, Lübeck
2025-06-23
Recruiting
A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease
NCT07239570Chronic Kidney Disease(CKD)
DrugsFinerenone·Semaglutide·Dapagliflozin
Peter Rossing
Phase 4
125
Hamburg
2025-06-20
Recruiting
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
NCT06972446Rheumatoid Arthritis
DrugsABBV-8736·ABBV-701·Lutikizumab·Adalimumab
AbbVie
Phase 2
180
Wetzlar, Bonn, Cologne, Hamburg
2025-06-20
Recruiting
TherVacB - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate
NCT06513286Chronic Hepatitis B
Michael Hoelscher
Phase 1/2
81
Frankfurt, Hamburg, Hanover, Leipzig, Munich
2025-06-12
Recruiting
A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia
NCT06953583Friedreich Ataxia
DrugsOmaveloxolone·Skyclarys
Biogen
Phase 3
255
Aachen, Giessen, Hamburg
2025-06-09
Recruiting
PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]
NCT06923111Sickle Cell Disease
Nova Laboratories Limited
Observational
180
Hamburg, Heidelberg
2025-06-09
Recruiting
Sputum-free Diagnostis of TB
NCT07125274Tuberculosis
Research Center Borstel
Observational
100
Hamburg
2025-06-06
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222Leukemia, Myeloid, Acute
DrugsBleximenib·Azacitidine·Venetoclax
Janssen Research & Development, LLC
Phase 3
600
Augsburg, Cologne, Dresden, Frankfurt, Freiburg im Breisgau, Hamburg, Heidelberg, Kiel
2025-06-04
Recruiting
Assessing Declined Liver Grafts With Normothermic Machine Perfusion to Reduce Transplant Waiting Time
NCT06874296Liver Transplantation, Liver Diseases, Surgery
Charite University, Berlin, Germany
Not applicable
186
Hamburg, Aachen, Bonn, Münster, Berlin, Hanover, München, Regensburg
2025-06-02
Active, closed
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
NCT07037277HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C
DrugsBemnifosbuvir-Ruzasvir·BEM/RZR·Sofosbuvir-Velpatasvir
Atea Pharmaceuticals, Inc.
Phase 3
880
Frankfurt am Main, Leipzig, Hamburg
2025-06-02
Not yet open
Expectation Effects on Emotional Processing
NCT07031804Expectation Effects on Emotional Processing
Universitätsklinikum Hamburg-Eppendorf
Not applicable
51
Hamburg
2025-06
Recruiting
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
NCT06961006Malignant Melanoma
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 2
160
Heidelberg, Frankfurt am Main, Cologne, Essen, Hamburg
2025-05-29
Recruiting
Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)
NCT06904872Short Bowel Syndrome, Malabsorption Syndromes, Short Gut Syndrome, Post-Op Complication
DrugCrofelemer
Napo Therapeutics, S.p.A.
Phase 2
18
Aachen, Berlin, Essen, Hamburg, Rostock
2025-05-29
Active, closed
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
NCT06782373VEXAS, VEXAS Syndrome
DrugPacritinib
Swedish Orphan Biovitrum
Phase 2
156
Tübingen, Munich, Hamburg, Düsseldorf, Dresden, Lübeck
2025-05-28
Recruiting
EURO-STIM Registry
NCT06971796Obstructive Sleep Apnea, Obstructive Sleep Apnea (OSA)
Inspire Medical Systems, Inc.
Observational
1,000
Hamburg, Lübeck, Magdeburg, Mannheim, Munich
2025-05-26
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
DrugsSacituzumab tirumotecan·Docetaxel·Paclitaxel·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
1,123
Aachen, Trier, Saarbrücken, Leipzig, Jena, Berlin, Hamburg
2025-05-22
Recruiting
Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa
NCT06940830Hemophilia A
DrugEfanesoctocog alfa
Swedish Orphan Biovitrum
Phase 4
250
Berlin, Bonn, Frankfurt am Main, Hamburg, Munich
2025-05-21
Recruiting
Towards a More Standardized Bicuspid Aortic Valve Repair: Rationale and Design of CONTOUR Trial - a Randomized Trial
NCT06869954Bicuspid Aortic Valve (BAV), Aortic Regurgitation Disease
University Hospital Augsburg
Not applicable
100
Augsburg, Frankfurt am Main, Leipzig, Hamburg
2025-05-21
Active, closed
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
NCT06966479Severe Asthma
DrugVerekitug
Upstream Bio Inc.
Phase 2
396
Hamburg, Berlin, Hessen, Leipzig, Bendorf, Mainz
2025-05-21
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
600
Essen, Hamburg, Leipzig, Munich, Oldenburg
2025-05-19
Recruiting
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
NCT06947993Atopic Dermatitis
Novartis Pharmaceuticals
Phase 2
224
Frankfurt am Main, Mainz, Bad Bentheim, Dresden, Hamburg, Heidelberg, Magdeburg, Münster
2025-05-16
Active, closed
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
NCT06993610Hidradenitis Suppurativa (HS)
Zura Bio Inc
Phase 2
225
Bad Bentheim, Bochum, Darmstadt, Dresden, Hamburg, Heidelberg, München, Münster
2025-05-16
Recruiting
EFESO: Study on Juvenile Onset Eosinophilic Fasciitis
NCT07348263Eosinophilic Fasciitis
Meyer Children's Hospital IRCCS
Observational
20
Hamburg
2025-05-15
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459Obesity, Overweight
DrugOrforglipron
Eli Lilly and Company
Phase 3
800
Essen, Hamburg, Leipzig, Munich, Oldenburg
2025-05-15
Recruiting
Surgical vs Transcatheter Aortic Valve Replacement in YOUNG Patients
NCT06861361Symptomatic Severe Aortic Stenosis
Ceric Sàrl
Not applicable
1,180
Frankfurt, Hamburg, München, Trier
2025-05-15
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,400
Essen, Hamburg, Leipzig, Munich, Oldenburg
2025-05-15
Active, closed
Study of GS-0151 in Participants With Rheumatoid Arthritis
NCT06902519Rheumatoid Arthritis
Gilead Sciences
Phase 1
65
Cologne, Hamburg, München
2025-05-14
By invitation
Development and Evaluation of a Digital Aftercare Program for Adolescents (12-17 Years) With Depressive Symptoms After Hospital Discharge (Mind-WIN Pilot Study) (Mind-WIN Pilot)
NCT07007247Depressive Disorder, Depression, Unipolar
Universitätsklinikum Hamburg-Eppendorf
Not applicable
120
Hamburg, Lubin, Stadtroda
2025-05-13
Recruiting
Guiding Opioid Administration by Nociception Level Index (NOL) in Patients With Regional Anesthesia
NCT06905340Nociceptive Pain, Pain, Postoperative, Analgesia, Postoperative, Anesthesia Recovery Period
Universitätsklinikum Hamburg-Eppendorf
Not applicable
240
Hamburg
2025-05-12
Recruiting
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
NCT07227246Intracerebral Hemorrhage
DrugRecombinant Factor VIIa
Joseph Broderick, MD
Phase 3
350
Heidelberg, Erlangen, Frankfurt am Main, Augsburg, Berlin, Hamburg, Tübingen
2025-05-06
Recruiting
Classification and Prediction of Difficult Awake Tracheal Intubation With Flexible Bronchoscopes
NCT06953414Anesthesia, Airway Management, Intubation, Intratracheal, Bronchoscopy
Universitätsklinikum Hamburg-Eppendorf
Observational
313
Hamburg
2025-04-30
Active, closed
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895Type 1 Diabetes, Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
905
Bad Mergentheim, Bochum, Essen, Hamburg, Karlsburg, Leipzig, Münster, Oldenburg
2025-04-25
Active, closed
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
NCT06928142Sjogren Disease
DrugSibeprenlimab
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2
83
Freiburg im Breisgau, Cologne, Hamburg, München
2025-04-23
Recruiting
Brain Signal Training to Enhance Affect Down-regulation
NCT06626789Borderline Personality Disorder
Central Institute of Mental Health, Mannheim
Phase 1/2
164
Freiburg im Breisgau, Giessen, Halle, Hamburg, Mannheim, Tübingen
2025-04-23
Recruiting
VASC-AF Study: Vascular Closure vs Manual Compression
NCT07414121Atrial Fibrillation
Asklepios proresearch
Not applicable
100
Hamburg
2025-04-22
Active, closed
Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
NCT06712563Pulmonary Disease, Chronic Obstructive
AstraZeneca
Observational
2,000
Hamburg
2025-04-17
Recruiting
Cerebellar Transcranial Alternating Current Stimulation (tACS) to Modulate Parkinson's Disease Tremor
NCT06993571Parkinson's Disease (PD), Tremor
Universitätsklinikum Hamburg-Eppendorf
Not applicable
10
Hamburg
2025-04-16
Recruiting
Comparison of Preoperative Frailty Assessment Tools
NCT06889545Frailty, Frailty in Older Adults, Frailty/Sarcopenia
Universitätsklinikum Hamburg-Eppendorf
Observational
584
Hamburg
2025-04-15
Recruiting
Awake Prone Positioning in Spontaneous Breathing Patients With Acute Hypoxic Respiratory Failure Due to Pneumonia
NCT06931938Acute Hypoxemic Respiratory Failure
Universitätsklinikum Hamburg-Eppendorf
Not applicable
342
Hamburg
2025-04-11
Recruiting
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671CLL, Chronic Lymphocytic Leukemia
DrugsIdelalisib·Tacabrutideg·Bendamustine·Venetoclax
BeOne Medicines
Phase 3
250
Augsburg, Berlin, Chemnitz, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg
2025-04-10
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
DrugsCDK4/6i·Inavolisib·Letrozole
Hoffmann-La Roche
Phase 3
450
Cologne, Dresden, Essen, Hamburg, Hanover, Heidelberg, Koblenz, Langen
2025-04-09
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)
DrugsAmrubicin·Lurbinectedin·Topotecan·Sacituzumab Govitecan
Gilead Sciences
Phase 3
695
Berlin, Bochum, Chemnitz, Esslingen am Neckar, Hamburg, Löwenstein, Minden, Munich
2025-04-04
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
NCT06863961Atopic Dermatitis
DrugAfimkibart
Hoffmann-La Roche
Phase 2
162
Freiburg im Breisgau, Bad Bentheim, Merzig, Chemnitz, Quedlinburg, Hamburg
2025-04-01
Recruiting
Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only
NCT06867705Cancer
Resilience
Phase 3
1,458
Augsburg, Bad Saarow, Bochum, Hamburg, Hanover, Hösbach, Kiel, Lübeck
2025-04-01
Active, closed
European Multicenter Validation of PCaVision: A Head-to-Head Diagnostic Accuracy Study Comparing Multiparametric Transrectal Ultrasound to MRI for Clinically Significant Prostate Cancer Detection
NCT06935487Prostate Cancer
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Not applicable
806
Bonn, Hamburg, Planegg
2025-04-01
Not yet open
Pre-Operative Treatment in REseCTable COlon CanceR
NCT06899477Colo-rectal Cancer, Colon Cancer, Colon Carcinoma
DrugsMFOLFOXIRI·MFOLFOX6·Folfox·Irinotecan
Dominik Paul Modest
Phase 3
714
Berlin, Berlin-Spandau, Chemnitz, Cologne, Dessau, Dortmund, Frankfurt, Hamburg
2025-04
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112Endometrial Cancer
DrugsTaxotere·Rilvegostomig·Paraplatin·Taxol
AstraZeneca
Phase 3
600
Berlin, Chemnitz, Dessau, Dresden, Düsseldorf, Essen, Hamburg, Kassel
2025-03-27
Recruiting
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781Esophageal Squamous Cell Carcinoma
DrugsIfinatamab Deruxtecan·Irinotecan·Docetaxel·Paclitaxel
Daiichi Sankyo
Phase 3
510
Berlin, Bonn, Dresden, Frankfurt am Main, Hamburg, Jena, Leipzig, Nuremberg
2025-03-27
Active, closed
Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma
NCT06731803Esophagogastric Adenocarcinoma
DrugTrastuzumab deruxtecan
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 1/2
36
Berlin, Chemnitz, Essen, Frankfurt am Main, Halle, Hamburg, Heidelberg, Jena
2025-03-25
Active, closed
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485Metastatic Castration-resistant Prostate Cancer
DrugsAbiraterone·Enzalutamide·Docetaxel
Celgene
Phase 3
960
Nürtingen, München, Lübeck, Jena, Bonn, Essen, Hamburg, Heidelberg
2025-03-13
Recruiting
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
NCT06869551Juvenile Psoriatic Arthritis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
60
Erlangen, Hamburg
2025-03-13
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)
DrugsBMS-986393·Carfilzomib·Pomalidomide·Daratumumab
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Munich, Hanover, Chemnitz, Leipzig, Magdeburg, Kiel, Berlin, Hamburg
2025-03-12
Recruiting
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT06792695Metastatic Colorectal Cancer
DrugsFOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)·Volrustomig·Bevacizumab
AstraZeneca
Phase 2
80
Berlin, Dresden, Essen, Hamburg, Marburg
2025-03-12
Recruiting
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
NCT06668181Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis
DrugBimekizumab
UCB Biopharma SRL
Phase 3
40
Berlin, Dresden, Freiburg im Breisgau, Hamburg, Sankt Augustin, Sendenhorst, Tübingen
2025-03-11
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
600
Leipzig, Magdeburg, Berlin, Hamburg, Herne
2025-03-10
Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996Mantle Cell Lymphoma, B Cell Lymphoma
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 3
300
Chemnitz, Frankfurt am Main, Halle, Hamburg, Mutlangen, München, Siegen
2025-03-05
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
1,088
Bad Bentheim, Bad Doberan, Ratingen, Leipzig, Berlin, Dresden, Hamburg, München
2025-03-03
Recruiting
COCONUT Study Concomitant PVI and LAAC
NCT06861673Atrial Fibrillation (AF)
Asklepios proresearch
Observational
60
Hamburg
2025-03-01
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer
DrugsTrastuzumab deruxtecan·Trastuzumab·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 3
726
Berlin, Chemnitz, Dresden, Frankfurt am Main, Hamburg, Heidelberg, Leipzig, München
2025-02-27
Active, closed
Digital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity
NCT06831994Asthma Bronchiale, Breast Neoplasms, Coronary Disease, Diabetes Mellitus, Type 2
Universitätsklinikum Hamburg-Eppendorf
Not applicable
659
Hamburg
2025-02-26
Recruiting
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
NCT06747949Sjögren's Syndrome
DrugDazodalibep
Amgen
Phase 3
844
Heidelberg, Bad Doberan, Greifswald Hansestadt, Hamburg
2025-02-25
Active, closed
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404Arthritis, Psoriatic
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
552
Bad Bentheim, Berlin, Dresden, Freiburg im Breisgau, Hamburg, Herne, Langenau, Minden
2025-02-21
Active, closed
Post Market Registry for GORE® TAG® Thoracic Branch Endoprosthesis
NCT06507865Aneurysm, Dissection, Aortic, TAA Thoracoabdominal Aortic Aneurysm, Thoracic Aortic Aneurysm
W.L.Gore & Associates
Observational
155
Hamburg, Heidelberg, Kiel, Münster
2025-02-20
Active, closed
Investigating the Effectiveness of Vimida
NCT06251518Long COVID, Post COVID-19 Condition
Gaia AG
Not applicable
160
Hamburg
2025-02-13
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347Chronic Rhinosinusitis With Nasal Polyps
DrugsItepekimab·Mometasone furoate
Sanofi
Phase 3
231
Berlin, Frankfurt, Hamburg, Landsberg, Münster, Tübingen, Wiesbaden, Würzburg
2025-02-12
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920Generalized Myasthenia Gravis
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
180
Frankfurt am Main, Gummersbach, Hamburg, Münster
2025-02-07
Active, closed
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236Platinum-resistant Ovarian Cancer
DrugsRina-S·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine
Genmab
Phase 3
530
Berlin, Bonn, Dresden, Düsseldorf, Essen, Frankfurt, Giessen, Hamburg
2025-02-07
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360Chronic Rhinosinusitis With Nasal Polyps
DrugsItepekimab·Mometasone furoate
Sanofi
Phase 3
216
Dresden, Hamburg, Leipzig, Mainz, Villingen-Schwenningen
2025-02-06
Recruiting
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
NCT06624670Pyoderma Gangrenosum
DrugsSpesolimab·Prednisolone·Prednisone
LEO Pharma
Phase 3
90
Berlin, Düsseldorf, Erlangen, Essen, Freiburg im Breisgau, Hamburg, Tübingen, Würzburg
2025-02-05
Recruiting
Prospective Assessment Project of AirwaY Management-related Incidents in Adult Anaesthesia Care PAPAYA III
NCT06117176Airway Complication of Anesthesia, Adverse Events
Insel Gruppe AG, University Hospital Bern
Observational
40,000
Berlin, Hamburg
2025-02-01
Active, closed
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT06291220Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsABBV-453·Obinutuzumab
AbbVie
Phase 1
4
Ulm, Halle, Kiel, Berlin, Hamburg
2025-01-27
Recruiting
Urethral PeRfusion Index-Guided Hemodynamic ManagemenT in Patients Having Major Abdominal Surgery: the UPRIGHT Randomized Feasibility Trial
NCT06799832Urethral Perfusion Index, Tissue Perfusion, Microcirculation
Universitätsklinikum Hamburg-Eppendorf
Not applicable
116
Hamburg
2025-01-21
Recruiting
EFFICACY OF INTRAOPERATIVE ARISTA POLYSACCHARIDE APPLICATION ON THE POSTOPERATIVE BLOOD LOSS IN PATIENTS UNDERGOING RARP FOR THE TREATMENT OF PROSTATE CANCER
NCT06822036Prostate Cancer (Adenocarcinoma), Blood Loss, Postoperative, Erectile Function
St. Antonius Hospital Gronau
Not applicable
362
Hamburg, Gronau, Leipzig
2025-01-16
Recruiting
Evaluation of an Interactive E-learning Environment to Enhance Digital Health Literacy in Cancer Patients
NCT07200453Neoplasms
Universitätsklinikum Hamburg-Eppendorf
Not applicable
660
Hamburg
2025-01-16
Active, closed
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
NCT06684847Primary Sjogrens Disease
DrugEfgartigimod PH20
argenx
Phase 3
631
Tübingen, Munich, Hamburg, Hanover
2025-01-15
Recruiting
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126Melanoma, Cutaneous Malignant
DrugsAnzu-cel·Lifileucel·Temodar·Dacarbazine
Immatics US, Inc.
Phase 3
360
Cologne, Berlin, Bonn, Dresden, Erlangen, Essen, Frankfurt am Main, Hamburg
2025-01-14
Active, closed
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343Relapsing-remitting Multiple Sclerosis (RRMS)
DrugOcrelizumab
Amgen
Phase 3
152
Bad Homburg, Böblingen, Dresden, Ebersberg, Essen, Hamburg, Heidelberg, Leipzig
2025-01-13
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
NCT06754462Rheumatoid Arthritis
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
120
Hamburg, Ratingen
2025-01-10
Recruiting
The REDUCE EU Study - Endobronchial Thermal Liquid Ablation (ETLA) for the Treatment of Emphysema
NCT06655428Emphysema or COPD, Emphysema, Emphysema, Pulmonary, COPD
Morair Medtech, LLC
Not applicable
30
Berlin, Gauting, Hamburg, Heidelberg
2025-01-10
Recruiting
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424Arthritis, Psoriatic
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
750
Berlin, Cologne, Dresden, Freiburg im Breisgau, Hamburg, Herne, Langenau, Ratingen
2025-01-09
Recruiting
Early Catheter-directed Treatment of High Risk Pulmonary Embolism
NCT06672081Pulmonary Embolism Acute Massive
Leipzig Heart Science gGmbH
Not applicable
210
Bad Krozingen, Bautzen, Bonn, Düsseldorf, Erfurt, Frankfurt am Main, Halle, Hamburg
2024-12-27
Recruiting
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574Heart Failure, Heart Failure With Reduced Ejection Fraction
Cytokinetics
Phase 3
1,800
Heidelberg, München, Würzburg, Hamburg, Erfurt, Jena, Mainz, Bad Nauheim
2024-12-19
Recruiting
REACH: RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization
NCT06922175Epilepsy With Uncontrolled Focal-onset Seizures
Aziende Chimiche Riunite Angelini Francesco S.p.A
Observational
200
Freiburg im Breisgau, Hamburg, Kork
2024-12-19
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Cologne, Leipzig, Jena, Aachen, Hamburg, Mainz, Nuremberg, Ulm
2024-12-17
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma
DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone
GlaxoSmithKline
Phase 3
520
Jena, Lübeck, Chemnitz, Cologne, Dresden, Hamburg, Hanover, Mainz
2024-12-16
Recruiting
UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
NCT06726720Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
AstraZeneca
Observational
300
Berlin, Dresden, Frankfurt am Main, Halle, Hamburg, Hanover, Heidelberg, Kassel
2024-12-16
Rows per page Showing 201–300 of 889
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/hamburg?page=3

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 889 of those studies with a site in Hamburg.

How many clinical trials are recruiting in Hamburg?

452 of the 889 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 34 have not yet opened recruitment, 387 are active but closed to new participants, and 16 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.